Unesbulin is under clinical development by PTC Therapeutics and currently in the Phase I, Phase II and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Unesbulin’s likelihood of approval (LoA) and phase transition for Anaplastic Astrocytoma took place on 05 Jul 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

In addition, the same event on 05 Jul 2022 increased Unesbulin’s Phase Transition Success Rate (PTSR) for Glioblastoma Multiforme (GBM), and increased PTSR for Pediatric Diffuse Intrinsic Pontine Glioma.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Unesbulin Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Unesbulin overview

Unesbulin (PTC-596) is under development for the treatment of glioblastoma multiforme, anaplastic astrocytoma, acute myeloblastic leukemia, acute lymphocytic leukemia, fibrosarcoma, leiomyosarcoma, pediatric diffuse intrinsic pontine glioma and advanced solid tumors such as epithelial ovarian, primary peritoneal or fallopian tube carcinoma, endometrioid adenocarcinoma.The drug candidate is administered orally. It is a small-molecule inhibitor of BMI1. It is developed based on GEMS technology.

PTC Therapeutics overview

PTC Therapeutics discovers, develops, and markets medicines for the treatment of rare disorders. Its marketed products include Evrysdi (risdiplam) for spinal muscular atrophy, Translarna (ataluren) and Emflaza (deflazacort) for the treatment of Duchenne muscular dystrophy. The company’s pipeline candidates target the treatment of Huntington’s disease; children with inherited mitochondrial disease; leiomyosarcoma; acute myelogenous leukemia; and aromatic L-amino acid decarboxylase deficiency. PTC Therapeutics works in collaboration with various biotechnology and pharmaceutical companies for advancing its pipeline candidates. The company operates through its subsidiaries in the US and Europe. PTC Therapeutics is headquartered in South Plainfield, New Jersey, the US.

Quick View Unesbulin LOA Data

Report Segments
  • Innovator
Drug Name
  • Unesbulin
Administration Pathway
  • Oral
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.